益赛普治疗强直性脊柱炎的临床疗效观察

Etanercept in treatment of ankylosing spondylitis

目的观察益赛普治疗强直性脊柱炎（AS）的临床疗效。方法符合AS诊断标准并处于活动期的患者45例采用完全随机设计方法分为治疗组和对照组，对照组22例给予传统治疗药物及对症治疗，疗程半年；治疗组23例在对照组治疗方案的基础上，前2个月给予益赛普，25mg／次，2次／周。治疗前、后主要观察指标包括活动性指数、功能性指数，晨僵时间、全身和脊柱疼痛程度等，次要观察指标包括扩胸度、枕壁距、Schober试验，血沉、C-反应蛋白及用药安全情况等。结果治疗组除2例经济困难未坚持治疗、1例出现下呼吸道感染而停止治疗外，余20例患者治疗半年后，多个主要观察指标中均有不同程度的改进，脊柱疼痛、晨僵时间均有明显的改善与好转，且疗效优于对照组（P〈0．05），总有效率90．0％。结论对于患有活动性强直性脊柱炎患者，在传统治疗药物基础上加用益赛普，能迅速减轻AS的症状和体征，并可改善AS患者的功能、活动范围和生活质量。

Objective To observe effects of Etanercept on treating patients with ankylosing spondylitis. Methods Forty-five cases ankylosing spondylitis patients were divided into 2 groups according to resourceful principle, The patients in the control group were given NSAIDS, methotrexate, sulfasalazine, and expectant treatment; the treatment group was given Etanercept 25mg/d plus, beside the medicine used in the control group. Course of treatment was mouths. BASDAI, BASFI, duration of morning stiffness, total body pain and spinal pand , chest expansion, finger to floor distance, occiput to wall distance, Schobers test, Hp and CRP were recorded. Results After 6 mouths, all patients had the improvement of symptoms with different degrees. Conclusion Our data indicated that Etanercept treating ankylosing spondylitis has a significant effects.